PMID- 16510370
OWN - NLM
STAT- MEDLINE
DCOM- 20060424
LR  - 20191109
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 22
IP  - 6
DP  - 2005 Nov-Dec
TI  - Effects of fluvastatin slow-release (XL 80 mg) versus simvastatin (20 mg) on the 
      lipid triad in patients with type 2 diabetes.
PG  - 527-42
AB  - The lipid triad is the association of small, dense (sd) low-density lipoprotein 
      (LDL), low high-density lipoprotein (HDL), and hypertriglyceridemia, all of which 
      play a role in coronary artery disease in patients with type 2 diabetes. Although 
      statins have demonstrated clear positive effects on cardiovascular 
      morbidity/mortality in patients with diabetes and on single components of the 
      lipid triad, it remains controversial whether they affect all components of the 
      triad in these patients. Therefore, we performed a single-center, parallel-group, 
      prospective, randomized, open-label, blinded-endpoint (PROBE)-type comparison of 
      fluvastatin extended-release (XL) 80 mg (n=48) and simvastatin 20 mg (n=46), each 
      given once daily for 2 months to patients with type 2 diabetes with the lipid 
      triad, who were enrolled after a 1-month lifestyle modification and dietary 
      intervention program. After fluvastatin therapy, LDL (-51%; P<.01), 
      apolipoprotein B (ApoB; -33%; P<.01), intermediate-density LDL (idLDL) (-14.3%; 
      P<.05), sdLDL (-45%; P<.01), and triglycerides (-38%; P<.01) were significantly 
      decreased, and HDL (+14.3%; P<.05) and apolipoprotein A-I (ApoA-I; +7%; P<.05) 
      were increased; large buoyant (lb) LDL did not change (P=NS). Simvastatin therapy 
      decreased LDL (-55.1%; P<.01), ApoB (-46%; P<.01), lbLDL (-33.3%; P<.05), idLDL 
      (-22.7%; P<.05), sdLDL (-33.3%; P<.05), and triglycerides (-47.9%; P<.01); HDL 
      was not changed (P=NS) after simvastatin, but ApoA-I was increased (+11.3%; 
      P<.01). HDL increases (P<.01) and sdLDL decreases (P<.01) were significantly 
      greater after fluvastatin compared with simvastatin therapy; LDL, triglycerides, 
      ApoB, and idLDL changes were similar after both therapies (P=NS), and lbLDL 
      decreases were greater with simvastatin therapy (P<.05). With both treatments, 
      classic mean LDL and ApoB target levels were achieved in most patients. We 
      conclude that the lipid triad can be controlled with fluvastatin XL 80 mg in 
      patients with type 2 diabetes.
FAU - Bevilacqua, Maurizio
AU  - Bevilacqua M
AD  - Endocrinology and Diabetes Unit and LORENZ Research Center, Department of 
      Medicine, Luigi Sacco Hospital (Vialba)-University of Milan, Milan, Italy.
FAU - Righini, Velella
AU  - Righini V
FAU - Barrella, Massimo
AU  - Barrella M
FAU - Vago, Tarcisio
AU  - Vago T
FAU - Chebat, Enrica
AU  - Chebat E
FAU - Dominguez, Ligia J
AU  - Dominguez LJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Fatty Acids, Monounsaturated)
RN  - 0 (Indoles)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Lipoproteins, LDL)
RN  - 4L066368AS (Fluvastatin)
RN  - AGG2FN16EV (Simvastatin)
MH  - Aged
MH  - Anticholesteremic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Fatty Acids, Monounsaturated/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Female
MH  - Fluvastatin
MH  - Humans
MH  - Hypertriglyceridemia/*drug therapy
MH  - Indoles/administration & dosage/adverse effects/*therapeutic use
MH  - Lipoproteins, HDL/*blood
MH  - Lipoproteins, LDL/*blood
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Simvastatin/adverse effects/*therapeutic use
EDAT- 2006/03/03 09:00
MHDA- 2006/04/25 09:00
CRDT- 2006/03/03 09:00
PHST- 2006/03/03 09:00 [pubmed]
PHST- 2006/04/25 09:00 [medline]
PHST- 2006/03/03 09:00 [entrez]
AID - 427 [pii]
AID - 10.1007/BF02849947 [doi]
PST - ppublish
SO  - Adv Ther. 2005 Nov-Dec;22(6):527-42. doi: 10.1007/BF02849947.